W. K. Henry

发表

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

S. Hammer, D. Katzenstein, M. Hughes, 1996, The New England journal of medicine.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Progression of carotid artery intima–media thickening in HIV-infected and uninfected adults

W. K. Henry, J. Currier, P. Tebas, 2007, AIDS.

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

W. K. Henry, D. Podzamczer, H. Stellbrink, 2021, Open forum infectious diseases.

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

W. K. Henry, C. Fichtenbaum, S. Evans, 2005, AIDS research and human retroviruses.

Carotid artery intima–media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure

W. K. Henry, J. Currier, H. Hodis, 2005, AIDS.

Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline—Reply

W. K. Henry, P. Tebas, 2007 .

Evaluation of safety devices for preventing percutaneous injuries among health-care workers during phlebotomy procedures--Minneapolis-St. Paul, New York City, and San Francisco, 1993-1995.

J. Gerberding, W. K. Henry, J. Thurn, 1997, MMWR. Morbidity and mortality weekly report.

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.

W. K. Henry, K. Tashima, C. Fichtenbaum, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.

W. K. Henry, K. H. Hullsiek, K. Lichtenstein, 2014, The Journal of infectious diseases.

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS

W. K. Henry, C. Crumpacker, H. Balfour, 1996, Antimicrobial agents and chemotherapy.

Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'.

W. K. Henry, J. Currier, H. Hodis, 2006, AIDS.

Strategies for control of zidovudine concentrations in serum

W. K. Henry, H. Balfour, C. Fletcher, 1995, Antimicrobial agents and chemotherapy.

CD4 Cell Loss: After 25 Years Still a Puzzle Explaining, Predicting, and Treating HIV-Associated

W. K. Henry, H. Lane, P. Tebas, 2009 .

Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.

H Clifford Lane, W. K. Henry, H. Lane, 2006, JAMA.

HIV RNA quantitation: marker of HIV infection.

W. K. Henry, N. Melroe, J. Simpson, 1997, The Journal of the Association of Nurses in AIDS Care : JANAC.

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

W. K. Henry, J. Neaton, J. Baker, 2008, AIDS.

The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms

W. K. Henry, J. Neaton, J. Baker, 2009, Current opinion in HIV and AIDS.

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.

W. K. Henry, J. Currier, J. Aberg, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

D. Katzenstein, W. K. Henry, P. Tebas, 2008, PloS one.

Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort.

W. K. Henry, M. Budoff, J. Brooks, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Management of HIV: a swing back to the future.

W. K. Henry, O. Alozie, Shulamith C. Bonham, 2009, Minnesota medicine.

W. K. Henry, K. Tashima, C. Fichtenbaum, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

The epidemiology of HIV/AIDS in Minnesota: current trends.

W. K. Henry, O. Alozie, Shulamith C. Bonham, 2009, Minnesota medicine.

Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

D. Katzenstein, W. K. Henry, P. Tebas, 2008, PloS one.